The Future of Lymphedema: Potential Therapeutic Targets for Treatment.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2023-06-01 DOI:10.1007/s12609-023-00491-5

Stav Brown, Adana C Campbell, Kevin Kuonqui, Ananta Sarker, Hyeung Ju Park, Jinyeon Shin, Raghu P Kataru, Michelle Coriddi, Joseph H Dayan, Babak J Mehrara

{"title":"The Future of Lymphedema: Potential Therapeutic Targets for Treatment.","authors":"Stav Brown, Adana C Campbell, Kevin Kuonqui, Ananta Sarker, Hyeung Ju Park, Jinyeon Shin, Raghu P Kataru, Michelle Coriddi, Joseph H Dayan, Babak J Mehrara","doi":"10.1007/s12609-023-00491-5","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to summarize the current knowledge regarding the pharmacological interventions studied in both experimental and clinical trials for secondary lymphedema.Recent findings: Lymphedema is a progressive disease that results in tissue swelling, pain, and functional disability. The most common cause of secondary lymphedema in developed countries is an iatrogenic injury to the lymphatic system during cancer treatment. Despite its high incidence and severe sequelae, lymphedema is usually treated with palliative options such as compression and physical therapy. However, recent studies on the pathophysiology of lymphedema have explored pharmacological treatments in preclinical and early phase clinical trials.Summary: Many potential treatment options for lymphedema have been explored throughout the past two decades including systemic agents and topical approaches to decrease the potential toxicity of systemic treatment. Treatment strategies including lymphangiogenic factors, anti-inflammatory agents, and anti-fibrotic therapies may be used independently or in conjunction with surgical approaches.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233555/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12609-023-00491-5","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 2

Abstract

Purpose of review: This review aims to summarize the current knowledge regarding the pharmacological interventions studied in both experimental and clinical trials for secondary lymphedema.

Recent findings: Lymphedema is a progressive disease that results in tissue swelling, pain, and functional disability. The most common cause of secondary lymphedema in developed countries is an iatrogenic injury to the lymphatic system during cancer treatment. Despite its high incidence and severe sequelae, lymphedema is usually treated with palliative options such as compression and physical therapy. However, recent studies on the pathophysiology of lymphedema have explored pharmacological treatments in preclinical and early phase clinical trials.

Summary: Many potential treatment options for lymphedema have been explored throughout the past two decades including systemic agents and topical approaches to decrease the potential toxicity of systemic treatment. Treatment strategies including lymphangiogenic factors, anti-inflammatory agents, and anti-fibrotic therapies may be used independently or in conjunction with surgical approaches.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

淋巴水肿的未来：潜在的治疗目标。

综述目的：本综述旨在总结目前在实验和临床试验中研究的继发性淋巴水肿药物干预的知识。最近的发现：淋巴水肿是一种进行性疾病，会导致组织肿胀、疼痛和功能残疾。在发达国家，继发性淋巴水肿最常见的原因是癌症治疗过程中对淋巴系统的医源性损伤。尽管淋巴水肿的发生率很高，后遗症也很严重，但它通常是通过压迫和物理治疗等姑息性选择来治疗的。然而，最近关于淋巴水肿病理生理学的研究已经在临床前和早期临床试验中探索了药物治疗。摘要：在过去的二十年里，已经探索了许多淋巴水肿的潜在治疗方案，包括全身药物和局部方法，以降低全身治疗的潜在毒性。治疗策略包括淋巴管生成因子、抗炎药和抗纤维化疗法可以单独使用或与手术方法结合使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.